Daily Cardiology Research Analysis
Analyzed 59 papers and selected 3 impactful papers.
Summary
Analyzed 59 papers and selected 3 impactful articles.
Selected Articles
1. Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: The ORBITA-CTO Trial.
In the first sham-controlled RCT of CTO PCI, PCI produced a substantial reduction in angina beyond placebo, yielding 30.6 additional angina-free days and improvements across Seattle Angina Questionnaire domains at 6 months. Robust blinding and daily symptom capture strengthen causal inference.
Impact: Provides high-level evidence that CTO PCI improves symptoms beyond placebo using rigorous sham control, informing patient selection and shared decision-making.
Clinical Implications: Supports offering CTO PCI to symptomatic single-vessel CTO patients for angina relief when optimized medical therapy is insufficient, while emphasizing patient-centered discussions about benefits, risks, and procedural complexity.
Key Findings
- CTO PCI improved the angina symptom score versus placebo (OR 4.38; 95% CrI 1.57–12.69).
- Patients had 30.6 additional angina-free days (95% CrI 11.1–50.7) over 6 months.
- Seattle Angina Questionnaire domains (angina frequency +10.7) and CCS class improved beyond placebo.
- Blinding of patients, staff, and researchers was maintained throughout.
Methodological Strengths
- Multicenter randomized, sham-controlled, blinded design with rigorous blinding procedures.
- Daily symptom capture via a validated app and standardized withdrawal/restart of antianginals.
Limitations
- Small sample size (n=50) and 6-month follow-up may limit precision and generalizability.
- Restricted to single-vessel CTO without bystander disease; not designed for hard outcomes.
Future Directions: Larger, longer sham-controlled trials assessing quality of life, exercise capacity, cost-effectiveness, and subgroup effects (e.g., ischemic burden, collateralization) are warranted.
BACKGROUND: Percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) is offered for symptom and quality of life improvement, despite the absence of blinded randomized evidence. OBJECTIVES: The aim of this study was to assess the efficacy of CTO PCI in the first randomized, placebo-controlled trial of CTO PCI. METHODS: ORBITA-CTO is a multicenter, randomized, blinded trial comparing CTO PCI with a placebo procedure. Patients had angina attributable to a single-vessel CTO, without bystander coronary disease. Angina symptoms were recorded daily using the ORBITA app. After dual-injection coronary angiography, patients were randomized to either CTO PCI or placebo. Blinding was maintained using auditory isolation and deep conscious sedation. Antianginal medications were stopped at randomization and reintroduced on a patient-initiated protocol. At the 6-month follow-up, assessments were repeated. The primary efficacy outcome was the angina symptom score, an ordinal scale combining the daily symptom burden assessed by the ORBITA app, antianginal use, and over-ride events. Secondary outcomes were symptom and quality of life questionnaires and blinding fidelity. RESULTS: Between October 19, 2021 and October 21, 2025, 50 patients were randomly assigned to CTO PCI (n = 25) or placebo (n = 25). One patient randomized to PCI was withdrawn during the procedure because of a complication. All 50 patients were included in the primary analysis. Compared with placebo, CTO PCI resulted in an immediate and sustained improvement in the angina symptom score (OR:
2. Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.
In a multicenter randomized trial of obese TAVR patients (n=260), tirzepatide reduced HALT (8.4% vs 21.6; p=0.002) and ≥mild PVL (10.7% vs 25.3%; p=0.006) at 6 months, alongside CRP and weight reductions without excess major bleeding. Findings support metabolic modulation as a novel strategy to improve bioprosthetic valve healing.
Impact: Introduces a cardio-metabolic therapy that improves structural valve outcomes post-TAVR, addressing a common complication in a high-risk obese population.
Clinical Implications: For obese TAVR candidates, peri-procedural tirzepatide may reduce HALT/PVL and improve valve hemodynamics; integration with antithrombotic strategies and weight management should be individualized pending further confirmatory trials.
Key Findings
- HALT reduced at 6 months with tirzepatide (8.4%) vs control (21.6%); p=0.002.
- ≥Mild PVL reduced with tirzepatide (10.7%) vs control (25.3%); p=0.006.
- CRP and body weight decreased without an increase in major bleeding.
- Multivariable analysis implicated tirzepatide use and >30% CRP reduction as protective factors.
Methodological Strengths
- Prospective, randomized, multicenter design targeting a prespecified high-risk phenotype (obesity).
- Imaging-based endpoints (HALT, PVL) with concurrent biomarker (CRP) assessment.
Limitations
- Open-label design with imaging surrogate endpoints at 6 months; long-term clinical outcomes not assessed.
- Generalizability limited to obese patients; dosing/timing strategies require optimization.
Future Directions: Conduct blinded, event-driven trials assessing stroke, valve thrombosis, rehospitalization, and mortality; compare against other GLP-1/GIP regimens; elucidate mechanisms with advanced CT/4D flow imaging.
BACKGROUND: Obesity is increasingly recognized as a critical modifier of outcomes following transcatheter aortic valve replacement (TAVR), predisposing patients to subclinical leaflet thrombosis (SLT), hypo-attenuated leaflet thickening (HALT), and paravalvular leak (PVL). Metabolic inflammation, endothelial dysfunction, and pro-thrombotic states associated with obesity contribute to impaired bioprosthetic valve healing. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated robust metabolic, anti-inflammatory, and vascular protective effects. However, its impact on post-TAVR valve performance has not been previously evaluated. OBJECTIVES: To determine whether tirzepatide therapy initiated before TAVR and continued post-procedure reduces the incidence of HALT and PVL in obese patients undergoing TAVR. METHODS: TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m RESULTS: Among 260 randomized patients, tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, p = 0.002) and ≥ mild PVL (10.7% vs 25.3%, p = 0.006) at 6 months. Tirzepatide was associated with marked reductions in CRP and body weight without an increase in major bleeding. Multivariable analysis identified tirzepatide use, CRP reduction >30%, and BMI <32 kg/m CONCLUSIONS: Metabolic modulation with tirzepatide significantly improves post-TAVR valve healing and hemodynamics in obese patients. These findings introduce a novel cardio-metabolic strategy to reduce structural valve complications following TAVR. TRIAL SUMMARY: TAVR-MET STUDY: The TAVR-MET trial was a prospective, randomized, multicenter study designed to evaluate whether metabolic modulation with tirzepatide, a dual GIP/GLP-1 receptor agonist, could improve bioprosthetic valve outcomes following transcatheter aortic valve replacement (TAVR) in obese patients. Obesity is increasingly recognized as a key determinant of post-TAVR complications, particularly subclinical leaflet thrombosis (HALT) and paravalvular leak (PVL), driven by chronic inflammation, endothelial dysfunction, and a prothrombotic state. Tirzepatide has demonstrated potent weight-reducing, anti-inflammatory, and vascular protective effects, but its role in structural valve outcomes had not previously been explored. The trial enrolled 260 obese patients (BMI ≥ 30 kg/m
3. Spatiotemporal Deep Learning for Scar Screening in CMR: Toward Selective Use of Gadolinium.
A spatiotemporal DL model trained on cine CMR identified patients unlikely to have scar with AUC 0.79 (internal) and 0.78 (external), outperforming a spatial-only model and maintaining high sensitivity (86%/82%). This supports selective LGE use, potentially reducing gadolinium exposure and scan times.
Impact: Demonstrates generalizable, multi-vendor DL triage to avoid contrast in many CMR referrals, aligning with safety, cost, and workflow priorities.
Clinical Implications: Cine-only DL triage could screen out patients unlikely to have scar, reserving gadolinium for those with higher pretest probability, improving throughput and minimizing nephrogenic systemic fibrosis risk.
Key Findings
- Spatiotemporal DL outperformed spatial-only model: internal AUC 0.79±0.02 vs 0.70±0.05 (p<0.05); external AUC 0.78 vs 0.64 (p<0.001).
- Identified 64% (internal) and 52% (external) of patients without scar while maintaining high sensitivity (86% and 82%).
- Model trained and validated across multi-vendor, 1.5T/3T scanners, supporting generalizability.
Methodological Strengths
- Large internal training and independent multicenter external validation across vendors and field strengths.
- Ablation comparison to spatial-only model demonstrating incremental value of temporal features.
Limitations
- Diagnostic model without prospective clinical impact assessment or randomized implementation study.
- Specificity trade-offs and center-level biases may affect real-world performance.
Future Directions: Prospective trials integrating DL triage into CMR workflows to quantify contrast avoidance, cost, safety, and patient-centered outcomes; calibration across indications and sites.
BACKGROUND: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) is the gold standard for assessing myocardial scar. However, a substantial proportion of patients referred for CMR scar assessment are ultimately found to have no evidence of myocardial scarring. PURPOSE: To develop and evaluate a deep learning (DL) model capable of identifying patients without myocardial scar using cine imaging alone, thereby obviating the need for contrast administration and LGE imaging in these individuals. MATERIALS AND METHODS: We developed a novel spatiotemporal DL architecture to identify patients unlikely to have myocardial scar using contrast-free cine images. The model was trained on short-axis cine images from a consecutive cohort of 3,000 patients (1,753 males; mean age 54 ± 18 years) undergoing CMR for evaluation of known or suspected cardiovascular disease, using 1.5 and 3T scanners from Siemens and GE. External validation was performed in an independent multicenter cohort of 1,792 patients where images were acquired on 1.5T and 3T scanners from Siemens and Philips. The architecture utilizes factorized convolutions to extract spatial and temporal features and incorporates residual attention mechanisms to emphasize features most predictive of scar presence on LGE imaging. To evaluate the incremental value of incorporating temporal information, a second model was developed that excluded the temporal kernel from the DL architecture. Both models were trained and optimized using the same training dataset and were evaluated based on similar internal and external testing cohorts. Model performance in identifying patients without myocardial scar was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. RESULTS: The spatiotemporal model had a higher AUC compared to the spatial model in the internal (0.79±0.02 vs. 0.70±0.05, p<0.05, n=500) and external cohort (0.78 vs. 0.64, p<0.001, n=1792). The spatiotemporal model correctly identified 64% and 52% of patients without scar in the internal and external test sets, while maintaining a high sensitivity (86% and 82%). CONCLUSIONS: Incorporating temporal information from cine images using an end-to-end spatiotemporal DL architecture enables non-contrast screening for myocardial scar.